DCAT Sharp Sourcing 2017 will provide solution-focused insights for delivering value in an environment marked by increasingly complex global supply chains, greater cost pressures, and dynamic business conditions.
DCAT Sharp Sourcing 2017 features separate morning sessions for buyers and suppliers, a joint afternoon session for all attendees, followed by a keynote presentation and networking reception.
Morning Session: Suppliers' Forum: CDMOs, CMOs, and Suppliers will start the day in a forum of their peers that will allow them to gain customer-centric insights, through presentations and Q&A, on:
Market Overview: Financing and Partnering
Gain a Wall Street view on the financing and key partnerships activity of small-to-mid-sized pharma companies and the financial outlook for suppliers, CMOs, and CDMOs.
Strategies for Successfully Defending Regulatory Starting Materials Worldwide
The selection and justification of starting materials for drug substances is important for regulatory purposes as well as in defining project scope and cost in external development and manufacturing. Learn about the latest developments from the FDA, EMA, and ICH and the impact on pharma customer–supplier requirements.
Best Practices in Outsourcing: Pharma Companies’ Perspectives
How can you take your projects to the next level? Gain first-hand feedback from pharma companies on best practices and lessons learned and how they can be applied in the pharmaceutical manufacturing value chain.
Joint Afternoon Sessions: Buyers and suppliers will attend these sessions for solution-focused practical insights.
API Market Outlook (Supply & Demand)
Get the latest global market data and trends on demand and supply for active pharmaceutical ingredients (small molecules and biologics) for innovator and generic drugs in developed and emerging markets.
Chief Procurement Officer (CPO) Roundtable: Challenges and Solutions
CPOs address key challenges facing Procurement and provide insight on company initiatives to drive results: optimizing operating models through global shared services; Big Data analytics in procurement; creating a brand for the global procurement function; and supplier-enabled innovation.
Supply-chain financing is designed as a “win-win” for customers and suppliers in meeting working capital requirements, and it is taking root in the pharmaceutical industry. Learn whether it is a solution for your company.
Get the latest on DCAT’s benchmarking study, Value-Based Metrics, and how it can benefit your company.
Leading Your Team
Networking Reception: Plan to stay and enjoy this time for networking!
The Suppliers' Forum is designed for contract service providers and suppliers of products and services used in chemical, biopharmaceutical, and pharmaceutical development and manufacturing, packaging, and the related supply chain. Key job functions of attendees include:
Registration Requirements: To deliver targeted insight and create a comfortable environment for attendees, DCAT and its planning committees respectfully require that attendees of the Suppliers' Forum only be from contract service providers and suppliers. DCAT reserves the right to reassign registrants to the appropriate track.
Registration includes the continental breakfast, morning and afternoon education sessions, luncheon, keynote address and networking reception.
Attendees should pre-register and pre-pay for Sharp Sourcing 2017 before June 23, 2017 (5pm ET). Confirmations and receipts will be emailed to registrants when payment is received.
Daniel Cohen is a Managing Director at RBC Capital Markets, where he is responsible for healthcare mergers & acquisitions (M&A) and leads the firm’s pharmaceutical outsourcing and contract manufacturing practice. He is an accomplished M&A practitioner, having worked with and advised companies in the execution of M&A transactions valued at over $75 billion throughout his almost 20-year career.
Prior to joining RBC, he was a member of the Executive Leadership Team and Head of Global Corporate Development at Catalent, a Blackstone portfolio company, which completed its initial public offering in July 2014. He joined Catalent in 2010 and spearheaded the development and implementation of Catalent’s inorganic growth strategy, resulting in the completion of 14 transactions valued at approximately $1 billion. Prior to Catalent, Mr. Cohen spent 13 years on Wall Street, where he focused on healthcare M&A, including at JP Morgan and Bear Stearns.
Sean Johnston, PhD is the former Vice President of Manufacturing, Paratek Pharmaceuticals. He has more than 30 years of experience in the pharmaceutical industry, focusing on process development, manufacturing and operations. He began his career as a process manager for Bristol Myers-Squibb. Prior to joining Paratek, Dr. Johnston served as the Senior Vice President of Operations for Genaera Corporation. At Genaera and other start-up organizations, he managed development, manufacturing and analytical activities associated with a range of drug product candidates, including small molecules and biologics in multiple product formulations. He has made regulatory submissions in the US, Canada, and Europe and has hosted pre-approval inspections and general inspections by the US Food and Drug Administration and other regulatory authorities. Dr. Johnston has also worked for pharmaceutical contract manufacturers, including Lonza and Siegfried, where he was responsible for all aspects of commercial and clinical manufacturing, process improvement, technology transfer and facilities' expansion. Dr. Johnston received his MBA and PhD from the National University of Ireland.
Valdas Jurkauskas, PhD, is the Senior Director of Pharmaceutical Development and Manufacturing at Corbus Pharmaceuticals, where he is responsible for process development, manufacturing, supply chain and quality. Dr. Jurkauskas’ expertise is in chemical process development, small molecule drug substance and oral solid dose manufacturing, commercial process validation, and regulatory filings. Prior to joining Corbus, Dr. Jurkauskas led technical operations at STA Pharmaceuticals Co., Ltd., a WuXi AppTec Company, active pharmaceutical ingredient process development at Cubist Pharmaceuticals, which was acquired by Merck & Co., Inc., and was a member of Chemical Development team at Vertex Pharmaceuticals. Dr. Jurkauskas earned his PhD degree in organic chemistry at the Massachusetts Institute of Technology under the guidance of Professor Stephen L. Buchwald and his bachelor of science degree in chemistry at the University of Toronto.
Michael Semo is Advisor, External R&D Strategy, Small Molecule at Eli Lilly and Company, where he is responsible for the external R&D Strategy in small-molecule development. Michael has 19-plus years of experience in the pharmaceutical industry and has served in a variety of roles at Eli Lilly. He started his career in chemical product R&D, where he developed numerous commercial processes and enabled successful technical transfer to manufacturing. Over the past 10 years, he has been responsible for developing an integrated outsourcing strategy, focusing on drug substances, for both R&D and production activities. Before joining Lilly, he held a development chemist position at DowElanco for three years in the radiochemistry group.
Walter Charles is the Chief Procurement Officer at Biogen where his global procurement teams support the purchase of billions of dollars a year of products and services supporting research & development, manufacturing, marketing, legal, capital, IT, plant operations, travel, and general and administrative services for the $11-billion revenue/year biotechnology innovator.
Prior to joining Biogen, Mr. Charles held Chief Procurement Officer roles at companies such as Kraft Foods, Kellogg’s, Johnson & Johnson Consumer Supply Chain, and Cordis (one of J&J’s former medical devices companies). As such, he has the unique perspective of serving on supply-chain leadership teams, and leading procurement transformations across multiple industries, including biotechnology, consumer packaged goods, pharmaceutical and medical device businesses.
Mr. Charles holds an MBA from Columbia University; a master of engineering in environmental engineering from The Stevens Institute of Technology; and a bachelor’s of science from the United States Merchant Marine Academy.
Leonardo (Len) DeCandia, P.E. is Chief Procurement Officer, Johnson & Johnson (J&J). He has more than 30 years of experience in the pharmaceutical/healthcare/consumer products industries with expertise in engineering, manufacturing, procurement and end-to-end supply-chain management.
Len started his career at J&J, where over his original 15-year tenure, he held leadership positions in global engineering, operations and supply management. He returned to J&J in 2014 after holding significant supply-chain leadership roles in other Fortune 100 Companies and is currently the Chief Procurement Officer for J&J.
At the Roche Group, Len held assignments as both the Chief Procurement Officer for the diverse operating companies and as Vice President and Chief Supply Officer for the Roche N.A. Pharmaceutical Division. In these roles, along with end-to-end supply-chain responsibilities, Len pioneered the integration of traditional procurement responsibilities with the deployment of new practices in outsourcing for strategic areas such as contract manufacturing, contract research, and contract sales. He also introduced advanced practices in distribution and logistics, where in 2003, the Roche Pharmaceutical Supply Chain achieved the unprecedented accomplishment of winning all three major US Wholesalers Supplier of the Year Awards.
Len joined the AmerisourceBergen Corporation in 2004 as the Senior Vice President, Supply Chain Management/Corporate Procurement Officer. In this role, he led the pharmaceutical industry-wide transition from traditional buy-and-hold relationships to the advanced concept of fee-for-service manufacturer to distributor relationships. Len was responsible for introducing critical fundamental concepts, such as performance-based contracts and advanced collaboration practices that led to greater pharmaceutical supply-chain security and overall supply-chain efficiency in the US. Len received the ISM Crystal Award for the Purchasing Executive of the Year in 2005.
In 2009, Len became the Senior Vice President/Chief Procurement Officer for the Estee Lauder Companies (ELC), where he had responsibilities for both the supply chain and all other global sourcing. Len's team deployed a harmonized global SAP P2P platform, along with establishing a new and fully integrated global procurement team to cover all 50 affiliates in five regions for ELC. Len’s team also deployed advanced practices in sourcing, supplier management, category management, sustainability policies and practices, and supplier innovation.
Len is a founder and has served as Chair of the Rutgers Business School Supply Chain Management Center for more than10 years (Ranked 11th by US News & World Report). He is currently a member of the Rutgers Business School Advisory Board and is also an adjunct professor there where he teaches a graduate course in innovation management.
Mike Hoffman is Vice President of Global Procurement for Pfizer. The Global Procurement team partners with the internal Pfizer stakeholders to drive continuous improvement in cost, quality, and service from its external suppliers through effective sourcing, contracting, supplier management, and purchase transaction execution. The Global Procurement team supports all categories of spend, including production materials, contract manufacturing, capital, logistics, research and development, business technology, professional services, human resources and facilities. The Global Procurement team is also responsible for Pfizer’s Fleet and Travel programs and operations. Mr. Hoffman is a member of the Finance & Business Operations Leadership Team and the Senior Leadership Council. He also serves on the Board of Directors of the National Minority Supplier Development Council and the Women's Business Enterprise National Council.
Mr. Hoffman joined Pfizer in 1989 as an Assistant Buyer in what was then Pfizer Corporate Purchasing in the New York office. Since that time, he has held roles of increasing responsibility in both manufacturing site procurement and category management across varied spend categories.
Kate Kuhrt is Head of Go To Market, Life Sciences, at Clarivate Analytics, where she works with teams from across Clarivate Analytics to bring new solutions to market covering the entire life-sciences product lifecycle, ranging from drug discovery and translational research all the way to manufacturing, compliance, and generics. She has been working with the global generics and active pharmaceutical ingredient (API) manufacturing industries since 2002 when she joined Newport Strategies, which today forms the generics team of Clarivate Analytics, formerly the Intellectual Property and Science business of Thomson Reuters. For a number of years, Kate managed the generics and API intelligence content-creation teams and led the product development of the Newport suite of products.
Over the past decade, Kate has published a number of articles discussing the challenges and opportunities facing the global generics, biosimilars, and active ingredient manufacturing industries in different parts of the world and continues to present at conferences about developments in the generics and API space. Prior to joining Newport Strategies in 2002, Kate worked as an associate at the pharmaceuticals division of CRA International, a business and litigation consulting firm headquartered in Boston.
Erik Meader, PhD, is Senior Director of Global Procurement, Pfizer, where he leads the Program and Portfolio Management organization and is responsible for various strategic initiatives and performance-management programs across Global Procurement, including: Working Capital, Supplier Diversity, Decision Support, Communications, Professional Development, and Budgeting.
Dr. Meader joined Pfizer in 2001 and has led various organizations that focused on strategic sourcing, supplier relationship management, contract management, business process outsourcing, shared service centers, business process reengineering, procurement policies, and compliance programs. Prior to Pfizer, he worked in the management consulting, food and beverage, automotive, and oil and gas industries.
Dr. Meader has a PhD in organizational leadership from Eastern University, a MBA in finance from the University of Pittsburgh, and a bachelor of science in industrial engineering from Pennsylvania State University. He currently serves as an Adjunct Professor in the College of Business at Wilmington University, is Chairman of the Board for the Eastern Minority Supplier Development Council, and is on the Board of Fellows for the Organizational Leadership program at Eastern University.
Tommy Mitchell is Chief Procurement Officer at GE Healthcare. He has been with GE for 24 years, holding various positions in the supply-chain function in multiple sites across GE’s Aviation, Transportation, and Energy businesses. He led the Supply Chain for Distributed Power until he began his current role of Chief Procurement Officer for GE Healthcare in October 2015.
Prior to that, he served a sourcing role from 2003-2006 while based in Shanghai, China and Erie, Pennsylvania. In October 2006, he joined Inspection Technologies as the Global Supply Chain Leader working out of Bonn, Germany. From 2010 -2013, he served as the Supply Chain Leader for GE India and developed the Pune multi-modal factory.
He started his career in the Manufacturing Development Program immediately after receiving his engineering degree from Boston University. He received his MBA from the University of North Carolina in 1999 and was certified as a Six Sigma Master Blackbelt in 2002.
Keith Robinson is Associate Director, Global Supplier Performance and Development, Bristol-Myers Squibb Company, where he responsible for driving value through supplier performance improvements in the area of quality, delivery, and productivity. He is leading a global team that supports the Pharmaceutical Operating Unit and Biologics Development and Operations Organizations, addressing needs associated with specification, supplier relationship management, risk management, and total cost of ownership. He is a member of Procurement’s Global Manufacturing Services Leadership Team. Keith joined Bristol Myers Squibb as the Associate Director of Global Supplier Performance and Development Leader in December 2011. Prior to joining Bristol Myers Squibb, Keith was a plant manager for Toyota Motors Manufacturing in North America for nine years, and Delphi Automotive for seven years. During this period, Keith led teams that were responsible for supplier quality, plant quality, and lean manufacturing.
Keith holds a Bachelor’s of Science in Manufacturing Engineering and a Master’s of Science in Management Science and Executive Development from the Tuck School of Business at Dartmouth.
He is also a member of the DCAT Research & Benchmarking Task Force, which developed the current DCAT Benchmarking study, Value-Based Metrics, the results of which are scheduled to be released in September 2017.
Douglas J. Schoch is Vice President, Siemens Capital Company. As Vice President, Captive Business, Working Capital Finance, Mr. Schoch is responsible for the implementation and growth of the Siemens Supply Chain Finance program in North America, where Supply Chain Finance is an important part of Siemens’ initiative to improve working capital and manage supply-chain risk.
Mr. Schoch has more than 15 years of experience in applying trade finance solutions within various industries that have resulted in improved working capital positions and cash conversion cycle times. He holds a master of science in industrial relations from Rutgers University and a bachelor of science in industrial engineering from Pennsylvania State University as well as a graduate certification in supply chain management from the Smeal College of Business at Pennsylvania State University.
Keynote Speaker Phil Simms
"Leading Your Team"
Phil Simms is a 15-year veteran of the NFL who highlighted his career by leading his team to two Super Bowl Championships and was named Most Valuable Player of Super Bowl XXI. He also penned the New York Times bestseller, Sunday Morning Quarterback: Going Deep on the Strategies, Myths and Mayhem of Football.
Simms is a Quarterback Skills Expert and provides evaluations to top NFL personnel directors. He is also a co-owner and contributor to The Experts Network (TXN), an interactive digital sports network that specializes in the development of digital and original programming, repurposed content and high-end special events. Simms is a resident of Franklin
Lakes, NJ where he resides with his wife, Diana. They have three children and two grandchildren.
Hyatt Regency New Brunswick
Two Albany Street
New Brunswick, New Jersey 08901
Map & Directions
If you need to cancel your registration, you must do so by contacting the DCAT organization at +1-800-640-DCAT. Cancellation of a pre-registration before June 20, 2017 by 5:00pm ET will be refunded in full.
If cancellation of pre-registration is between June 20, 2017 and June 23, 2017 by 5 pm ET, the refunded amount will be reduced by the food and beverage guarantee given to the hotel per registrant. Refunds will not be provided for no-shows.
Registration payments made by credit card will be refunded within two to three business days from the date of cancellation.
Registration payments made by check will be refunded within 20 days of the program date.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.